Effect of hormone replacement therapy on serum complement (C3, C4) and immunoglobulin (IgG, IgM) levels in post-menopausal women

Abstract

Serum C3, C4, IgG and IgM levels were evaluated in healthy post-menopausal women receiving short-term hormone replacement therapy (HRT) regimens and in untreated women. Serum C3, C4, IgM and IgG levels were assessed in 54 women receiving HRT therapy (CEE 0.625 mg+MPA 2.5 mg/day), and in 54 control women not receiving HRT. The results showed that the mean serum C3 and C4 levels were significantly higher in women receiving HRT than those untreated women (P<0.01). There was significant difference in IgG and IgM levels between two groups. It was concluded that HRT might be involved in the development of cardiovascular diseases through inflammatory mechanisms, as suggested by increased serum levels of C3 and C4.

Keywords

hormone replacement therapy / complement / immunoglobulin

References

[1] HeikinenJ., VaheriR., KainulainenP., et al.. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high and low dose estrogen regiments. J Osteoprs Int, 2000, 11: 929-935

[2] RossouwJ. E., AndersonG. L., PrenticeR. L., et al.. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA, 2002, 288: 321-333

[3] MaasA. M., Van Der GraafY., Van Der SchouwY. T., et al.. HRT and heart disease: problems and prospects. Maturitas, 2004, 47: 255-264

[4] WagnerJ. D., KaplanJ. R., BurkmanR. T.. Reproductive hormones and cardiovascular disease mechanism of action and clinical implications. Obstet Gynecol Clin North Am, 2002, 29: 475-482

[5] HulleyS., GradyD., BushT., et al.. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA, 1998, 280: 605-612

[6] BaldoA., SnidermanA. D., St-LuceS., et al.. The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J Clin Invest, 1993, 92: 1543-1549

[7] MuscariA., MassarelliG., BastagliL., et al.. Relationship of serum C3 to fasting insulin, risk factors and previous ischemic events in middle-aged men. Eur Heart J, 2000, 21: 1081-1086

[8] MuscariA., MassarelliG., BastagliL., et al.. Relationship between serum C3 levels and traditional risk factors for myocardial infarction. Acta Cardiol, 1998, 53: 345-350

[9] YilmazerM., FenkciY., FenkciS., et al.. Association of serum complement (C3, C4) and immunoglobulin (IgG, IgM) levels with hormone replacement therapy in healthy post-menopausal women. Hum Reprod, 2003, 18: 1531-1535

[10] KovanenP. T., ManttariM. P. T., et al.. Prediction of myocardial infarction in dislipidemic men by elevated levels of immunoglobulin classes A, E, and G, but not M. Arch Intern Med, 1998, 158: 1434-1438

[11] MuscariA., PudduP.. Immunoglobulins C3 and the risk of myocardial infarction. Arch Intern Med, 1999, 159: 2364-2371